Combining encorafenib and cetuximab with pembrolizumab in MSI-high (MSI-H)/dMMR and BRAF V600E-mutant mCRC patients was founded on the concept that tumor progression in this specific subgroup is driven by both genomic instability (reflected by MSI-H/dMMR) and BRAF-mutation-induced MAPK signaling, which are potential therapeutic targets. Here, BRAF is linked to neoplasm.